• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Anticipation Is Running High for Canadian Cannabis Sales

Wednesday is the first day for legalized cannabis sales in Canada.
By DEBRA BORCHARDT
Oct 16, 2018 | 01:31 PM EDT
Stocks quotes in this article: TLRY, CGC, ACBFF

October 17 is the first day for adult use cannabis sales in Canada and the anticipation is running, dare we say it, high. Market watchers will be looking to see if there are lines out the dispensary doors similar to what Colorado and California experienced on the first day of such sales.

News crews will be out interviewing customers and dispensary owners alike. Brands will be wondering whether the plain packaging for all of the products will hurt sales. Cannabis companies themselves will be wringing their hands and hoping for the best. E-commerce executives will be hoping the systems can handle the hoped-for crush of traffic. This is unknown territory.

The expectations are running high since the U.S. states that legalized adult use cannabis experienced big surges in sales. Recently, Nevada legalized adult use cannabis and dispensaries reported bare shelves as producers couldn't keep up with demand.

Illegal dispensaries had already been popping up in Canada - a sign that demand existed. Still these companies have spent enormous sums of money to build these businesses and the shareholders will be wondering if it was worth it. They are watching to see how long this break-even will take and when these companies will be profitable.

There is an old stock market adage that you buy the rumor and sell the news. Several of these Canadian cannabis companies have experienced huge runups in valuation with multiples not seen in other industries. Many expect that Wednesday's first day of sales could cause a sel off in the stocks.

"People might rush to sell," said John Torrens, a professor of entrepreneurship at Syracuse University's Whitman School and an expert in the business end of the marijuana industry. "My personal thought is that companies that are medical only might see a little margin compression. Some companies may suffer a little bit, but the fact is the market is projected to grow quickly and demand is high and will continue to go up."

Companies like Tilray (TLRY) have shot from $65 at the end of August to lately trading at around $160. Canopy Growth (CGC) has moved from $45 at the end of August to around $54. Aurora Cannabis (ACBFF) closed at $6.68 on August 31 and is now trading at around $11.

Shares of all three companies were down by about 4-5% early afternoon on Tuesday.

"I think part of the rich valuations is part of irrational exuberance, sure there could be some dips in the short term," Torrens added. Still, he believes legalization is helpful because bigger or institutional money can get involved. "Short-term dips aside the potential for higher valuations are still there."

Another analyst, Matt Karnes, the founder of GreenWave Advisors, pointed out that a lot of dispensaries won't be open on Wednesday and that some provinces will be doing most of its business online. This will make it harder to determine if the sales are really happening.

"My crystal ball is in front of me and I expect we'll see some selloff, but then a recovery. The stocks will gradually trade on fundamentals and not news flow," he said. "The movements on the slightest bit of news is not warranted. Like Tilray announcing they could export cannabis to the University of California. The DEA only authorized 5,400 pounds and that didn't warrant the rise in the stock."

Karnes added, "They'll all say they have record sales, but it will be interesting to see the initial audited financial statements and see what real accounting firms say when they have to do their work." Karnes also noted that determining the value of biological assets is complicated. "How can you clearly identify the value of these assets? A lot of question marks remain."

Indeed. The companies will continue to report "record sales" for the first four quarters as they have no comparisons to make. They are also heading into the holiday season. Cannabis sales in legal markets have been easily documented as spiking during the holidays. Sales in the U.S. jump for Thanksgiving and Christmas. No doubt Boxing Day will see its fair share of big sales.

Investors will have to look at the claims of record sales with skepticism and look to comparisons between the company sales. They will need to compare province to province and company to company to get a good idea of success. Investors that feel as if they missed this latest stock run may be tempted to buy the dips, but they should also be aware that a year from now when real comparisons are made, the stocks may begin to come back down to earth.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication Borchardt had no position in the securities discussed.

TAGS: Investing

More from Investing

Bearish Bets: 2 NYSE Stocks You Should Consider Shorting This Week

Bob Lang
Jan 24, 2021 10:30 AM EST

These names are displaying both quantitative and technical deterioration.

Price Targets: How They Mislead and How They Can be Used

James "Rev Shark" DePorre
Jan 23, 2021 10:00 AM EST

The main problem with price targets is that they are a static number in a dynamic situation.

Stock Market Continues to Defy Conventional Wisdom

James "Rev Shark" DePorre
Jan 22, 2021 5:04 PM EST

Concerns about the action being overheated remain, but rotational action keeps the momentum going.

AMC Is a High Risk, High Reward Play

Timothy Collins
Jan 22, 2021 2:15 PM EST

Short and sweet: This is based on the high running emotions of the markets. There's little to it beyond that.

GoodRx Needs a Shot in the Arm to Improve Its Outlook

Bruce Kamich
Jan 22, 2021 2:03 PM EST

IPOs in recent months have done extremely well -- not so GDRX.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    I discuss price targets in my Saturday column.
  • 07:54 AM EST GARY BERMAN

    Friday Morning Fibocall for 1/22/2021

    SPX (Long-Term View) The 1/21/21 NEW high @ 3861...
  • 11:16 AM EST CHRIS VERSACE

    Worst Stocks to Buy for the Biden Presidency

    Biden's take on the minimum wage, likely moves on ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login